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Abstract
Butyrates and retinoids are promising antineoplastic
agents. Herewe analyzed effects of sodiumbutyrate and
N -(4-hydroxyphenyl)-retinamide (4-HPR) on prostate
cancer cells as monotherapy or in combination in vitro
and in vivo. Sodium butyrate and 4-HPR induced
concentration-dependent growth inhibition in prostate
cancer cells in vitro. The isobologram analysis revealed
that sodium butyrate and 4-HPR administered together
antagonize effects of each other. For the in vivo studies,
awater-soluble complex (4-HPRwith a cyclodextrin)was
created. A single dose of sodium butyrate and 4-HPR
showed a peak level in chicken plasma within 30 min-
utes. Both compounds induced inhibition of prolifer-
ation and apoptosis in xenografts of the chicken
chorioallantoic membrane. Analysis of the cytotoxic
effects of the drugs used in combination demonstrated
an antagonistic effect on inhibition of proliferation and
on induction of apoptosis. Prolonged jun N-terminal
kinasephosphorylation inducedbysodiumbutyrate and
4-HPR was strongly attenuated when both compounds
were used in combination. Both compounds induced
inhibitionofNF-KB.This effectwasstrongly antagonized
in LNCaP cells when the compounds were used in
combination. These results indicate that combinational
therapies have to be carefully investigated due to
potential antagonistic effects in the clinical setting
despite promising results of a monotherapy.
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Introduction
Treatment options for early-stage prostate cancer are well
defined, and localized prostate cancer can be cured by
several strategies. Yet, in advanced prostate cancer dis-
ease, the therapeutic outcome is still disappointing [1].
Conventional chemotherapy has not proven to be suffi-
ciently effective and is often limited by toxicity [2]. Recent trials
with Docetaxel (Sanofi-Aventis, Bridgewater, NJ) in advanced
disease are promising, although the survival benefit is still
rather limited [3]. Hence, there is considerable need to identify
well-tolerated and easily applicable substances either for
chemoprevention of prostate cancer in high-risk patients or
for adjuvant chemotherapy in advanced stages.
Agents active against prostate cancer alter cell growth and
differentiation by interfering with pathways regulating crucial
cell functions. Butyrates, histone deacetylase inhibitors (HDA-
CIs), as well as retinoids, derivates of retinoic acid, are exam-
ples of such compounds.
Butyrates are naturally occurring short-chain fatty acids
leading to inhibition of tumor cell growth. It has been shown
that butyrates can induce cell cycle arrest, differentiation, and
apoptosis in many tumor cell types, whereas having a favorable
safety profile in humans [4]. We have previously demonstrated
that sodium butyrate and tributyrin strongly induce growth
inhibition and apoptosis in different human prostate cancer cell
lines in vitro [5] and on chicken chorioallantoic membrane
(CAM) and in nude mice in vivo [6].
Naturally occurring retinoids possess significant chemo-
preventive effects in neoplasias such as acute promyelocytic
leukemia [7]. Yet the role of retinoids in prostate cancer is still
poorly understood. N-(4-Hydroxyphenyl)-retinamide (4-HPR) is
a synthetic retinoid that has shown antitumor activity in prostate
cancer in animal models [8,9]. Compared with the naturally
occurring retinoids, 4-HPR is expected to be more effective with
fewer side effects, as it may selectively target specific apoptosis-
related pathways in prostate cancer [10]. Mitogen-activated
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protein kinase (MAPK) pathways phosphorylate numerous
proteins including transcription factors, cytoskeletal proteins,
and kinases and thus influence cell proliferation and apop-
tosis [11]. There is some evidence that jun N-terminal kinase
(JNK) and extracellular signal-regulated kinase (ERK)/MAPK
pathwaysmight be involved in sodium butyrate– and 4-HPR–
mediated cytotoxicity [12–14].
In this study we explored in vitro the antiproliferative
effects of sodium butyrate and 4-HPR, as single drugs and
in combination, on two prostate cancer cell lines. We also
developed a drug application system for the highly lipophilic
4-HPR, converting it into a water-soluble complex that
could be applied intravenously in a clinical setting. Further-
more, we analyzed the pharmacokinetics of sodium butyrate
and 4-HPR in vivo in the CAM model. The treatment effects
on xenografts were evaluated by immunohistochemistry,
using the proliferation marker Ki-67, and by terminal deoxy-
nucleotidyl transferase–mediated dUTP nick end labeling
(TUNEL) assay.
Materials and Methods
Reagents
All reagents were obtained from Sigma-Aldrich (Munich,
Germany). A stock solution of sodium butyrate was pre-
pared in sterile water. 4-HPR was dissolved in DMSO for the
in vitro experiments or in sterile water as a b-cyclodextrin
derivate complex for the in vivo studies.
Analysis of Growth Inhibition in Cell Culture
The drug-induced effects were evaluated on the hormone-
sensitive LNCaP cells and hormone-independent PC-3 cells
(ATCC, Wesel, Germany). The cell lines were cultured in
RPMI 1640 (PromoCell, Heidelberg, Germany) and used
for the experiments in a growing phase. Cell proliferation
was measured by Cell Proliferation Kit II (Roche, Penzberg,
Germany) based on the XTT assay. LNCaP (5  103) and
PC-3 (2  103) cells were grown in microtiter plates and
treated with the drugs for 72 hours. Drug interaction was
analyzed by the isobologram method [15].
Preparation of the 4-HPR/-Cyclodextrin Complex
for In Vivo Testing
For the solubilization of 4-HPR in water, different cyclo-
dextrins and derivatives thereof were tested. Because of
the size of 4-HPR, a (2-hydroxypropyl)-b-cyclodextrin (CD)
has been chosen. A 4-HPR/CD complex at a molar ratio of
1:14 was used. The maximum solubility for the 4-HPR/CD
at room temperature is 0.2 g/ml water, corresponding to a
10 mM solution of 4-HPR.
Chicken Chorioallantoic Membrane Assay
The xenotransplantations onto CAMs of fertilized chicken
eggs were carried out as previously described [16,17].
Briefly, at day 7 of fertilization, a double-silicone ring (6 mm;
distance between rings, 3 mm) was placed onto the CAM.
The cells (1  106) were seeded onto one ring in 20 ml 50%
Matrigel (BD Biosciences, Heidelberg, Germany) in serum-
free RPMI 1640. Starting on the day after inoculation the
drugs were administered onto the second ring three times
daily for 4 days. Tumor tissues were sampled, fixed, paraffin-
embedded, and serially sectioned (5 mm). Slides were pro-
cessed for staining and immunohistochemistry for human
cytokeratin and Ki-67 [16,17] (antibodies from Dako, Ham-
burg, Germany). The images were digitally recorded at 50
magnification with an Axiophot microscope (Carl Zeiss,
Jena, Germany) and a Sony (Ko¨ln, Germany) MC-3249
CCD camera using Visupac 22.1 software (Zeiss). Photo-
micrographs were analyzed with Optimas 6.51 from Media
Cybernetics (Silver Spring, MD).
For the in situ detection of apoptotic cells in paraffin-
embedded tissue sections, the TUNEL method was used
(Roche Diagnostics). The sections were counterstained
with hematoxylin.
To determine the drug plasma levels, drugs were applied
once and blood was drawn from the chorioallantoic vessels
at different time points.
Pharmacokinetic Analysis of Sodium Butyrate
and 4-HPR in Plasma
Plasma was purified by PS-OH solid-phase extraction
chromatography and analyzed by HPLC using Reprosil-Pur
ODS3 column (Dr. Maisch GmbH, Ammerbuch, Germany).
The concentrations of compounds were calculated by the
dynamic linear calibration method using dilutions of standard
compounds [18]. The intra-assay coefficient of variation was
11.7% for sodium butyrate and 3.1% for 4-HPR. The inter-
assay coefficients of variation were 9% and 6% for sodium
butyrate and 4-HPR, respectively (n = 3).
Western Blot Analysis
Cells were treated for 3 hours with individual compounds or
in combination. Whole-cell lysates containing equal amounts
of protein were separated by SDS-PAGE, transferred to
Polyvinylidene diflouride (PVDF) membranes, probed with
specific antibodies, and detected as described previously
[17]. Antibodies for phosphorylated forms of p38, JNK,
ERK1/2, InBa (all from Cell Signaling, Danvers, MA) were
used. Actin (Chemicon, Hampshire, UK) was used as a
loading control.
Statistical Analysis
The drug effects were statistically evaluated using
Newman-Keuls test. Values are presented as mean ± SEM.
P values <.05 were considered statistically significant.
Results
Drug-induced Inhibition of Cell Proliferation In Vitro
The PC-3 and LNCaP prostate cancer cell lines were
treated with increasing concentrations of sodium butyrate
and 4-HPR for 72 hours. A 50% growth inhibition of LNCaP
cells was achieved by sodium butyrate at a concentration of
3.0 mM and 0.87 mM 4-HPR (Figure 1, A and B). The IC50 for
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4-HPR was 0.32 mM in the presence of 2 mM sodium buty-
rate, and 0.69 mM with 1 mM sodium butyrate (Figure 1C).
Drug interactions were analyzed by the isobologram method
[15]. The IC50 values for each drug used as a monotherapy
were placed on the x- and y-axis and connected by a line,
which is the locus of points that produce a simple additive
effect. In the presence of 1 to 2 mM sodium butyrate the
concentrations of 4-HPR that induced 50% inhibition of
proliferation of LNCaP cells are located above the line, which
clearly indicates antagonistic effects (Figure 1D). Similarly,
the IC50 of sodium butyrate and 4-HPR in PC-3 cells were
2.8 mM and 2.48 mM, respectively (Figure 2, A and B). In the
presence of sodium butyrate the IC50 for 4-HPR was slightly
reduced to 2.10 and 1.43 mM with 1 and 2 mM sodium
butyrate, respectively (Figure 2, C and D). The data indicate
that sodium butyrate and 4-HPR antagonize effects of each
other in both cell lines.
Pharmacokinetics of Sodium Butyrate and 4-HPR
in the CAM Model
For in vivo analysis of cytotoxic effects of the drugs in
LNCaP and PC-3 tumors xenografted on the CAM, we
created a water-soluble 4-HPR/CD complex (Figure 3A).
Single doses of sodium butyrate (5 mmol) and 4-HPR/CD
(0.6 mmol) were applied on the CAM (Figure 3B) and the
pharmacokinetics were analyzed (Figure 3, C and D). The
maximum plasma level of sodium butyrate was detected
20 minutes after application, and of 4-HPR, 30 to 40 minutes
after application. Under these conditions t1/2 was 17 minutes
for sodium butyrate and 90 minutes for 4-HPR.
Effect of Sodium Butyrate and 4-HPR on Prostate
Tumor Xenografts on CAM
Tumors were transplanted onto the CAM and treated with
20 mmol sodium butyrate and 0.6 mmol 4-HPR/CD either as
monotherapy or in combination three times a day for 4 days.
CD was used as control and had no effect either on prolifera-
tion or on the apoptosis in xenografts. Both sodium butyrate
and 4-HPR inhibited proliferation (number of Ki-67–positive
cells) of LNCaP and PC-3 tumors growing on the CAM
(Figures 4 and 5). The amount of apoptotic cells of untreated
LNCaP cells was already too low to allow statistical analysis.
About 22% of PC-3 cells were Ki-67 positive. Treatment
with either sodium butyrate or 4-HPR significantly reduced
the number of proliferating cells (Figure 5B). Interestingly,
when both compounds were applied simultaneously, 4-HPR
Figure 1. Inhibitory effect of sodium butyrate and 4-HPR as monotherapy or in combination on proliferation of LNCaP cells. Cells were treated in vitro for 72 hours
with increasing concentrations of sodium butyrate (A), 4-HPR (B), or 1 to 2 mM sodium butyrate and increasing concentrations of 4-HPR (C). Cell proliferation was
analyzed by a modified formazan assay (XTT). The number of viable cells in the control group was set to 100%. Results are presented as mean ± SEM of three
experiments. (D) Detection of the antagonistic effects of sodium butyrate and 4-HPR on proliferation of LNCaP by using the isobologram method. The IC50 of
4-HPR in the presence of 2 mM sodium butyrate is 0.32 M and in the presence of 1 mM sodium butyrate is 0.69 M. The values lie above the line connecting two
points representing the IC50 of 4-HPR and sodium butyrate used alone indicating the antagonistic effects of drugs.
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antagonized the strong inhibitory effect of sodium butyrate
on cell proliferation. Similarly, treatment with sodium buty-
rate significantly increased apoptosis in PC-3 xenografts
(Figure 5C). 4-HPR in the concentration used had no effect
on the apoptosis in PC-3 cells, but reduced the proapoptotic
effect of sodium butyrate. Thus, compared with the in vitro
assay, sodium butyrate and 4-HPR showed strong antago-
nistic effects in the in vivo model.
Effect of Sodium Butyrate and 4-HPR on MAPK Activation
Analysis of MAPK activity by using antibodies against
phosphorylated/activated forms of kinases demonstrated
that LNCaP and PC-3 cells exhibit constitutively active p38
and ERK, but not JNK (Figure 6).Treatment of LNCaP and
PC-3 cells either with sodium butyrate or with 4-HPR trig-
gered a prolonged activation of JNK, which was reduced
when the combination of both compounds was used. Sodium
butyrate and 4-HPR had no effect on p38 activation in PC-3
cells (Figure 6), but sodium butyrate induced a marked
decrease in p38 activation in LNCaP cells, which was
abolished in the presence of 4-HPR (Figure 6). Both sodium
butyrate and 4-HPR inhibited constitutively active ERK1/2
in prostate cells.
LNCaP and PC-3 cells exhibited significant amounts of
phosphorylated InBa, indicating constitutive activation of
the NF-nB transcription factor. Sodium butyrate and 4-HPR
inhibited NF-nB in both cell lines. However, when both
compounds were added together, the NF-nB inhibition
was abolished in LNCaP cells. These data indicate that
MAPK as well as NF-nB pathways might be involved in
antagonistic effects of sodium butyrate and 4-HPR on pros-
tate cancer.
Discussion
As prostate cancer is one of the leading causes of deaths
caused by malignancies worldwide, there is a tremendous
need to identify active substances against this disease. Be-
cause of the heterogeneous pattern of prostate cancer, one
can hypothesize that a combination of different drugs af-
fecting various pathways involved in prostate cancer growth
and survival may be advantageous. In the present study we
Figure 2. Inhibitory effect of sodium butyrate and 4-HPR as monotherapy or in combination on proliferation of PC-3 cells. Cells were treated in vitro for 72 hours
with increasing concentrations of sodium butyrate (A), 4-HPR (B), or 1 to 2 mM sodium butyrate and increasing concentrations of 4-HPR (C). Cell proliferation was
analyzed by a modified formazan assay (XTT). The number of viable cells in the control group was set to 100%. Results are presented as mean ± SEM of three
experiments. (D) Detection of the antagonistic effects of sodium butyrate and 4-HPR on proliferation of PC-3 by using the isobologram method. The IC50 of 4-HPR
in the presence of 2 mM sodium butyrate is 1.43 M and in the presence of 1 mM sodium butyrate is 2.1 M. The values lie above the line connecting two points
representing the IC50 of 4-HPR and sodium butyrate used alone indicating the antagonistic effects of drugs.
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investigated an effect of a combination of an HDACI, sodium
butyrate, with a synthetic retinoid, 4-HPR, on the proliferation
and induction of apoptosis in prostate cell lines.
Malignant cells express increased histone deacetylase
activity. It is believed that inhibitors could normalize their
transcriptional activity. In fact, successful preclinical studies
have resulted in the evaluation of HDACIs in the clinical
setting [19]. Meanwhile new inhibitors such as suberoylanilide
hydroxamic acid (SAHA) [20,21], PXD-101 (TopoTarget,
Copenhagen, Denmark) and LAQ-824 (Novartis AG, Basel,
Switzerland) were developed.
Sodium butyrate exhibits growth inhibition in LNCaP and
PC-3 cells. These effects were apparently independent
of the p53 status because PC-3 cells, which are less differ-
entiated, carry mutated p53 [22]. Both cell lines, hormone-
sensitive LNCaP and hormone-independent PC-3, were
equally sensitive to sodium butyrate treatment.
4-HPR, a synthetic derivative of all-trans-retinoic acid, is
more effective against cancer cells compared with the natu-
rally occurring retinoic acids especially in hormone-dependent
diseases [23]. It exhibits antitumor activity in PC-3 cells in vitro
[24] and in prostate cancer xenografts in vivo [8,25]. Clinical
pilot trials with 4-HPR as monotherapy were less successful
[26]. However, 4-HPR is expected to act synergistically with
other chemotherapeutic drugs [27].
Similar to sodium butyrate, 4-HPR inhibited proliferation
of LNCaP and PC-3 cells independently of p53 status of
cells. When both substances were applied together, they
antagonized effects of each other, demonstrating potential
interference within signaling pathways.
Figure 3. Analysis of plasma pharmacokinetics of sodium butyrate and water-soluble 4-HPR/CD complex. (A) Top: structure of the (2-hydroxypropyl)--
cyclodextrin (CD) molecule consisting of seven glucopyranosides. Middle: structure of 4-HPR. Bottom: graphical presentation of 4-HPR within the CD molecule. (B)
Principle of CAM assay. For xenotransplantation of tumor cells onto CAM, cells were seeded in 20 l medium/Matrigel (1:1) in a 6-mm silicone ring placed on CAM
of fertilized chicken. Next day after seeding, drugs or the cyclodextrin vehicle were put onto the second ring. (C) For analysis of the plasma-level kinetics, 5 mol of
sodium butyrate in 20 l was applied topically on the CAM. Blood was collected from chorioallantoic veins at different time points, anticoagulated with 5 mM EDTA,
and used for plasma preparation. For each time point, blood from three eggs was analyzed. (D) Pharmacokinetic analysis of plasma levels of 4-HPR was performed
essentially as for sodium butyrate; 0.6 mol of 4-HPR in 15 l was applied topically on the CAM.
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Figure 4. Inhibitory effect of sodium butyrate and 4-HPR as monotherapy or in combination on proliferation of LNCaP cells in vivo in CAM assay. Histological and
TUNEL staining of representative center tissue sections of the LNCaP xenografts. Six days after fertilization, 1  106 cells were grafted onto the CAM of chicken eggs.
Next day, the CAMs were topically treated with either sodium butyrate (20 mol/20 l), 4-HPR/CD (0.6 mol/15 l), or both substances three times a day for 4 days.
Sections were stained with hematoxylin-eosin (HE), human cytokeratin, and Ki-67 proliferation antigen and photomicrographed at 50 magnification. Apoptosis was
analyzed by TUNEL technique, counterstained with hematoxylin, and photomicrographed at 100 magnification. Data shown are representative of 4 to 6 eggs each.
Figure 5. Inhibitory effect of sodium butyrate and 4-HPR asmonotherapy or in combination on proliferation of PC-3 cells in vivo in CAM assay. (A) Histological and TUNEL
staining of representative center tissue sections of the PC-3 xenografts. Six days after fertilization, 1 106 cells were grafted onto the CAMs of chicken eggs. Next day, the
CAMs were topically treated either with sodium butyrate (20 mol/20 l), 4-HPR/CD (0.6 mol/15 l), or both substances three times a day for 4 days. Sections were
stained with hematoxylin-eosin (HE), human cytokeratin, and Ki-67 proliferation antigen and photomicrographed at 50 magnification. Apoptosis was analyzed by TUNEL
technique, counterstained with hematoxylin, and photomicrographed at 100 magnification. Data shown are representative of 4 to 6 eggs each. (B) Histomorphometric
analysis of the proliferation antigen Ki-67. For histomorphometry we used digitalized color photomicrographs of serial 5-m sections 100 m apart from each other (n =
4–6 eggs in each group). All treatment groups expressed significantly less Ki-67 antigen than the cyclodextrin control group. Results aremean ± SEM of 4 to 6 eggs in each
group. *P < .05, **P < .01 compared with control. (C) Histomorphometric analysis of apoptosis. Results presented as percent of terminal deoxynucleotidyl transferase
(TdT)–positive cells. **P < .01.
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We further analyzed if the antagonistic effects of the drugs
also occurred in vivo. Sodium butyrate induced pronounced
growth inhibition and induced apoptosis in PC-3 xenografts.
4-HPR as a monotherapy reduced cell proliferation but had
no effect on the level of apoptosis. Application of both drugs
in combination reduced antiproliferative and proapoptotic
effects seen with sodium butyrate as monotherapy. Thus,
both substances act antagonistically in vitro and in vivo.
Limited information exists concerning interactions of reti-
noids with other antineoplastic agents. Our results, showing
the antagonistic effects between 4-HPR and sodium buty-
rate, prompted us to analyze the possible molecular mecha-
nisms of this antagonism.
Antagonistic effects of 4-HPR on sodium butyrate–
induced apoptosis might be a result of interference with the
pro- and antiapoptotic signaling pathways, such as MAPK.
MAPKs, which include ERK1/2, JNKs, and p38, are activated
by phosphorylation [11]. ERK1/2 is constitutively activated in
various tumors and associated with cell proliferation [11].
Inactivation of ERK might be involved in HDACI-mediated
lethality [13,14]. Treatment of LNCaP and PC-3 with either
sodium butyrate or 4-HPR drastically reduced ERK activity,
which might contribute to the inhibitory effects on the pro-
liferation of prostate tumor cells.
Members of the JNK family regulate cellular responses to
various stresses. Transient JNK activation is associated with
gene expression and cell proliferation, whereas prolonged
JNK activation promotes cell death [28]. Histone deacetylase
inhibitors have been shown to use JNK for induction of apop-
tosis [14]. In contrast, retinoids, in particular 4-HPR, strongly
suppress c-jun (which is a JNK substrate) activity, and thus,
activator protein 1 activity in ovarian cancer [29]. In prostate
cancer cells, 4-HPR induced JNK activation leading to the
induction of apoptosis [12]. We have found that treatment of
prostate cells with either sodium butyrate or 4-HPR triggers
prolonged JNK activation; coadministration of both drugs
resulted in downregulation of JNK phosphorylation and, con-
sequently, inhibition of apoptosis in prostate cells.
The prolonged activation of JNK induced by sodium buty-
rate and 4-HPR might be a result of concomitant downregu-
lation of NF-nB activity, which triggers increased reactive
oxygen species (ROS) [30] NF-nB is a family of transcription
factors regulating expression of antiapoptotic genes [28].
Consequently, inhibition of NF-nB activity promotes apoptosis
in prostate cancer cells [17]. Sodium butyrate and 4-HPR
suppressed phosphorylation of the inhibitor InBa, resulting in
the inhibition of NF-nB activation and downregulation of
expression of antiapoptotic genes. This effect was abolished
in LNCaP when both compounds were used in combination,
rending cells less susceptible to apoptosis.
Together our data show that sodium butyrate and 4-HPR
inhibit ERK1/2 and NF-nB, activate JNK, and thus possess
inhibitory effects on prostate cancer cells in vitro and in vivo.
Applied together, sodium butyrate and 4-HPR, however,
antagonize effects of each other. Studies on the molecular
mechanism of action of antineoplastic drugs are the key to
allow the identification of highly effective agents and the
development of efficacious combinations for targeted ther-
apy of the heterogeneously growing prostate cancer.
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